Evidence map›Paper›PMID 33218054›Full record

ReviewInternational journal of molecular sciences2020

Developmental Programming and Reprogramming of Hypertension and Kidney Disease: Impact of Tryptophan Metabolism.

Chien-Ning Hsu, You-Lin Tain

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
14.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Serotonin dysfunction in ADHD.Journal of neurodevelopmental disorders · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Amino acid metabolism in kidney health and disease.Nature reviews. Nephrology · 2024
    Review
  15. Article
  16. Article
  17. Article
  18. Cardiovascular Health Starts in the Womb.Hypertension (Dallas, Tex. : 1979) · 2024
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Chien-Ning HsuDepartment of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, Taiwan.ORCID 0000-0001-7470-528X
You-Lin TainDepartment of Pediatrics, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung 833, Taiwan.ORCID 0000-0002-7059-6407
Chang Gung University · TWKaohsiung Medical University · TW

Funding

Chang Gung Memorial Hospital, Kaohsiung, Taiwan CMRPG8J0891 and CMRPG8J0253
6 · The paper itself

Abstract

The concept that hypertension and chronic kidney disease (CKD) originate in early life has emerged recently. During pregnancy, tryptophan is crucial for maternal protein synthesis and fetal development. On one hand, impaired tryptophan metabolic pathway in pregnancy impacts fetal programming, resulting in the developmental programming of hypertension and kidney disease in adult offspring. On the other hand, tryptophan-related interventions might serve as reprogramming strategies to prevent a disease from occurring. In the present review, we aim to summarize (1) the three major tryptophan metabolic pathways, (2) the impact of tryptophan metabolism in pregnancy, (3) the interplay occurring between tryptophan metabolites and gut microbiota on the production of uremic toxins, (4) the role of tryptophan-derived metabolites-induced hypertension and CKD of developmental origin, (5) the therapeutic options in pregnancy that could aid in reprogramming adverse effects to protect offspring against hypertension and CKD, and (6) possible mechanisms linking tryptophan metabolism to developmental programming of hypertension and kidney disease.

Indexed as

AnimalsFemaleFetal DevelopmentGastrointestinal MicrobiomeHumansHypertensionMetabolic Networks and PathwaysPregnancyRenal Insufficiency, ChronicTryptophanTryptophanaryl hydrocarbon receptorchronic kidney diseasedevelopmental origins of health and disease (DOHaD)hypertensionindolekynureninemelatoninserotonintryptophanuremic toxin

Identifiers

PMID33218054
PMCPMC7698939
OpenAlexW3104174267

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.